PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
10.44%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
10.28%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
12.12%
EPS growth of 12.12% while AXSM is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
10.49%
Diluted EPS growth of 10.49% while AXSM is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
2.21%
Share reduction more than 1.5x AXSM's 10.64%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Negative OCF growth while AXSM is at 3.01%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-28.93%
Negative FCF growth while AXSM is at 2.68%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
52.56%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
56.42%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-10058.37%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
92.69%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
51.37%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
741.48%
10Y equity/share CAGR above 1.5x AXSM's 302.76%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
108.54%
Below 50% of AXSM's 302.76%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-89.94%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Negative asset growth while AXSM invests at 185.46%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-40.69%
We have a declining book value while AXSM shows 1574.25%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
499.58%
Debt growth far above AXSM's 180.04%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-14.73%
Our R&D shrinks while AXSM invests at 6.32%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.54%
SG&A declining or stable vs. AXSM's 22.59%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.